Genomtec S.A.: Umowa partnerstwa dotycząca komercjalizacji platformy Genomtec® ID na terenie Tajwanu (2022-08-10)

Signing of commercial partnership agreement for Genomtec® ID sales in Taiwan.

The Management Board of Genomtec S.A. ("Issuer", "Company") announces that today, i.e., 10 August 2022, it signed an agreement (the "Agreement") with a Commercial Partner, a Company operating in Poland with its subsidiary headquartered in Taipei, Taiwan (the "Partner"), pertaining business opportunities identification that should lead to local commercial agreements signing for market adoption of the Genomtec® ID platform (the ”Product”) in Taiwan (the “Territory”). Pursuant to the Agreement, the Partner will support the Issuer qualifying the leads and their propensity in signing commercial agreements for distributorship, wholesale, re-sale of the Products on the Territory, along with Partner’s in-field marketing activities, and regulatory consulting for the Product sales authorisation in the Territory.

The Partner is a renowned innovative, Polish-Japanese biotechnology firm that specialises in the go-to-market strategy especially for South Asia, focusing on the nutraceuticals and medical diagnostics devices. In addition to diagnostics, Partner's activities focus on R&D and commercialization of innovative solutions in the field of biotechnology. The Partner operates internationally, working closely with top Japanese and Taiwanese suppliers and experts in the field of biotechnology.

The Company's Management Board considered the fact of concluding the Agreement to be confidential information, as the implementation of the aforementioned Agreement may have a significant impact on the Issuer's future revenue situation, as well as on the popularization of the Company's technology and Product. Therefore, this information, in the opinion of the Management Board, meets the criteria for confidential information within the meaning of Article 17 (1) of MAR.